Remedium Lifecare Ltd
Incorporated in 1988, Remedium Lifecare Ltd is in the business of trading in Advanced Pharmaceutical Intermediates and other pharma products
- Market Cap ₹ 79.4 Cr.
- Current Price ₹ 0.90
- High / Low ₹ 18.0 / 0.80
- Stock P/E
- Book Value ₹ 1.03
- Dividend Yield 0.00 %
- ROCE 1.76 %
- ROE 3.55 %
- Face Value ₹ 1.00
Pros
- Stock is trading at 0.87 times its book value
- Company has a good return on equity (ROE) track record: 3 Years ROE 51.2%
Cons
- Though the company is reporting repeated profits, it is not paying out dividend
- Company has low interest coverage ratio.
- Promoter holding is low: 1.13%
- Company might be capitalizing the interest cost
- Company has high debtors of 969 days.
- Working capital days have increased from 21.4 days to 68.6 days
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Peer comparison
Services Services Commercial Services & Supplies Trading & Distributors
Quarterly Results
Standalone Figures in Rs. Crores / View Consolidated
Profit & Loss
Standalone Figures in Rs. Crores / View Consolidated
| Mar 2007 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | TTM | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | 2 | 4 | 1 | 0 | 0 | 3 | 90 | 505 | 510 | 4,040 | 222 | 147 | |
| 1 | 2 | 4 | 1 | 0 | 0 | 2 | 89 | 503 | 502 | 4,006 | 222 | 161 | |
| Operating Profit | 0 | -0 | -0 | -0 | 0 | -0 | 0 | 1 | 2 | 8 | 34 | 1 | -14 |
| OPM % | 3% | -8% | -8% | -7% | 0% | -44% | 14% | 1% | 0% | 2% | 1% | 0% | -9% |
| 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 21 | 11 | 15 | |
| Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 5 | 8 | 2 |
| Depreciation | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Profit before tax | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 1 | 2 | 7 | 50 | 4 | -1 |
| Tax % | 50% | 21% | 0% | 0% | 0% | 100% | 24% | 26% | 29% | 27% | 35% | 58% | |
| 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 5 | 33 | 2 | -2 | |
| EPS in Rs | 0.00 | 0.01 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.01 | 0.01 | 0.06 | 0.37 | 0.02 | -0.02 |
| Dividend Payout % | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% |
| Compounded Sales Growth | |
|---|---|
| 10 Years: | 59% |
| 5 Years: | 138% |
| 3 Years: | -24% |
| TTM: | -96% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | 10% |
| 5 Years: | 40% |
| 3 Years: | 12% |
| TTM: | 51% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | % |
| 5 Years: | 2% |
| 3 Years: | -38% |
| 1 Year: | -94% |
| Return on Equity | |
|---|---|
| 10 Years: | 41% |
| 5 Years: | 48% |
| 3 Years: | 51% |
| Last Year: | 4% |
Balance Sheet
Standalone Figures in Rs. Crores / View Consolidated
| Mar 2007 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Sep 2025 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 4 | 4 | 4 | 4 | 4 | 4 | 4 | 4 | 4 | 4 | 10 | 40 | 88 |
| Reserves | -0 | -1 | -1 | -1 | -1 | -1 | -0 | 0 | 1 | 7 | 33 | 3 | 3 |
| 1 | 0 | 0 | 0 | 0 | 0 | 0 | 10 | 0 | 0 | 58 | 1,141 | 1,088 | |
| 1 | 3 | 2 | 0 | 0 | 0 | 1 | 24 | 219 | 1,144 | 1,847 | 355 | 351 | |
| Total Liabilities | 6 | 6 | 5 | 3 | 3 | 4 | 4 | 39 | 224 | 1,154 | 1,948 | 1,540 | 1,529 |
| 2 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 6 | |
| CWIP | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 9 |
| 4 | 4 | 5 | 3 | 3 | 4 | 4 | 38 | 224 | 1,154 | 1,948 | 1,540 | 1,515 | |
| Total Assets | 6 | 6 | 5 | 3 | 3 | 4 | 4 | 39 | 224 | 1,154 | 1,948 | 1,540 | 1,529 |
Cash Flows
Standalone Figures in Rs. Crores / View Consolidated
| Mar 2007 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 0 | -1 | 0 | -0 | -0 | -0 | -10 | 11 | 20 | -74 | -1,079 | ||
| 0 | 1 | 0 | 0 | 1 | -0 | -0 | -0 | -0 | 0 | 0 | ||
| -0 | -0 | 0 | 0 | 0 | 0 | 10 | -11 | -0 | 54 | 1,078 | ||
| Net Cash Flow | -0 | 0 | 0 | -0 | 1 | -0 | -0 | 1 | 20 | -20 | -0 |
Ratios
Standalone Figures in Rs. Crores / View Consolidated
| Mar 2007 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debtor Days | 120 | 341 | 265 | 596 | 2,117 | 319 | 189 | 96 | 46 | 123 | 83 | 969 |
| Inventory Days | 1,129 | 243 | 78 | 0 | 0 | 5 | 12 | 455 | ||||
| Days Payable | 102 | 438 | 129 | 62 | 65 | 542 | ||||||
| Cash Conversion Cycle | 1,147 | 146 | 214 | 596 | 2,117 | 319 | 189 | 96 | 46 | 67 | 30 | 882 |
| Working Capital Days | 566 | 107 | 200 | 524 | 2,159 | 4,745 | 323 | 54 | 2 | -8 | 4 | 69 |
| ROCE % | 1% | 1% | 0% | 1% | 1% | 11% | 7% | 18% | 103% | 100% | 2% |
Documents
Announcements
- Shareholder Meeting / Postal Ballot-Scrutinizer"s Report 8 Dec
-
Shareholder Meeting / Postal Ballot-Outcome of Postal_Ballot
8 Dec - Postal ballot approved name change to Supha Pharmachem; appointed Vignesh Gawde and Rambhajan Vishwakarma effective 31 Oct 2025.
-
Announcement under Regulation 30 (LODR)-Newspaper Publication
17 Nov - Newspaper Publication for unaudited financial results 30.09.2025
-
Announcement under Regulation 30 (LODR)-Press Release / Media Release
17 Nov - Q2 Sep-30-2025 PAT ₹3,862.34 lakh; H1 PAT ₹31,327.22 lakh; board appointments.
-
Results - Financial Results For Quarter And Half Year Ended September 30, 2025
14 Nov - Board approved unaudited standalone and consolidated Q2/H1 results for quarter and half year ended 30 Sep 2025.
Annual reports
-
Financial Year 2025
from bse
-
Financial Year 2024
from bse
-
Financial Year 2023
from bse
-
Financial Year 2022
from bse
-
Financial Year 2021
from bse
-
Financial Year 2020
from bse
-
Financial Year 2019
from bse
-
Financial Year 2018
from bse
-
Financial Year 2017
from bse
-
Financial Year 2016
from bse
-
Financial Year 2015
from bse
-
Financial Year 2014
from bse
-
Financial Year 2013
from bse
-
Financial Year 2012
from bse
Business Overview:[1]
Company does trading and sale of API intermediates (KSMs & CRMs) and various other raw materials used in API trading to innovator and generic pharmaceutical players in Domestic and International markets